Skip to main content
European Commission logo print header

MEFISTO - Meniscal functionalised scaffold to prevent knee Osteoarthritis onset after meniscectomy

Project description

An innovative meniscus scaffold against osteoarthritis

Meniscal resection often leads to early osteoarthritis (OA), which necessitates alternative reconstructive strategies. The EU-funded MEFISTO project proposes to develop a functionalised nanomaterial-based scaffold capable of interacting with the native meniscal tissue. This innovative device will promote local revascularisation and help regenerate the native meniscus, especially in younger patients. At the same time, it will deliver drugs locally to modulate tissue inflammation in patients with advanced OA. Given the considerable number of individuals undergoing meniscectomy, the MEFISTO interventions will improve surgery outcomes and reduce OA-related co-morbidities.

Objective

MEFISTO will develop two novel solutions to treat meniscus loss as a strategy for preventing the onset of an epidemic of post-meniscectomy knee osteoarthritis (OA) in Europe. Morphological profiling will identify the population of patients who, after meniscal resection, are at higher risk of early compartment degeneration, providing a personalized approach for the patient. The two different reconstructive strategies are: i) a controlled vascularized bioactive biodegradable meniscal scaffold, which will regenerate the native meniscus. This strategy will address younger patients with early osteoarthritic changes. ii) a bioactive non-biodegradable meniscal prosthesis, which will act as a mechanical unloading device and a drug delivery system, with the capacity to modulate the inflammatory environment. This strategy will address patients with advanced OA. A socio-economic analysis of the efficacy of existing meniscal substitutes will complete the project. This analysis is of vital importance for the European healthcare system, as it will provide a clear understanding of the costs and benefits of current clinical practice and predict the impact of the two new interventions. The technological innovation lies in the development of biologically active functionalized nanobiomaterials that can interact with the surrounding articular tissues. The biodegradable scaffold will promote revascularization in the peripheral zone, while leaving the inner zone avascular, reflecting the native meniscal tissue and functionalization with drug delivery micro/nanoparticles of the non-biodegradable device will provide modulation of inflammation. The impact is expected to be significant as so many patients have undergone or will undergo meniscectomy. The interventions developed in MEFISTO will prevent these patients from receiving joint-sacrificing procedures such as metal prosthesis whilst reducing the social burden, associated costs and high levels of morbidity resulting from OA.

Call for proposal

H2020-NMBP-TR-IND-2018-2020

See other projects for this call

Sub call

H2020-NMBP-TR-IND-2018

æ

Coordinator

GEISTLICH BIOMATERIALS VERTRIEBSGESELLSCHAFT MBH
Net EU contribution
€ 37 500,00
Address
Schneidweg 5
76534 Baden-baden
Germany

See on map

Region
Baden-Württemberg Karlsruhe Baden-Baden, Stadtkreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Other funding
€ 0,00

Participants (14)